Biogen Surges To Two-Month High On Delayed Review For Alzheimer’s DrugFinancial and Business News – Investor’s Business Daily | Stock News & Stock Market Analysis – IBD

Biogen stock popped Friday after the Food and Drug Administration extended the review period for the company’s controversial Alzheimer’s treatment.

Läs mer

Lämna ett svar

Din e-postadress kommer inte publiceras. Obligatoriska fält är märkta *